Top

Italian Journal of Pediatrics

Published in:

Open Access 01-12-2023 | Chronic Kidney Disease | Research

GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease

Authors: Naglaa Makram Farag, Mahmoud Mousa, Eman Elsayed, Ahlam Ismeil

Published in: Italian Journal of Pediatrics | Issue 1/2023

Abstract

Background

Anaemia is a common presenting feature among patients with chronic kidney disease (CKD) and associated with poor clinical outcomes. We evaluated the diagnostic validity of growth differentiation factor-15 (GDF-15) and hepcidin as it is not clear if they are useful as a biomarkers of anaemia among non-dialysis CKD egyptian patients.

Method

An analytical cross-sectional study was conducted among non-dialysis CKD patients (n = 60) and apparently healthy controls (n = 28) at Minia University maternity & children Hospital. Serum levels of GDF-15 and hepcidin were determined. Predictive logistic regression models were built and post estimation receiver operator characteristics were determined to evaluate diagnostic validity of hepcidin and GDF-15 for iron deficiency anaemia.

Results

Hepcidin and GDF-15 are significantly higher in cases than control p value (0.047 < 0.0001) respectively. The predictive value of diagnosing anaemia among CKD patients using hepcidin and GDF-15 was 72.0%, 70.0%. There was a weak negative correlation between hepcidin levels and glomerular filtration rate GFR (r = -.175, p = 0.105) in CKD patients, and significant correlation between serum GDF-15 and haemoglobin (r = -0.897, p < 0.0001), ferritin (r = 0.489, P < 0.000), Iron (r = -0.314, P = 0.002), CRP (r = 0.409, P < 0.0001).

Conclusion

Hepcidin and GDF-15 is a potential biomarker for predicting anaemia connected with inflammation among CKD Egyptian patients.

Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol. 2014;29(9):1493–505. https://doi.org/10.1007/s00467-013-2557-x.

Ganz T. Anemia of inflammation. N Engl J Med. 2019;381:1148–57. https://doi.org/10.1056/NEJMra1804281.CrossRefPubMed

Aeddula NR, Bardhan M, Baradhi KM. Sickle Cell Nephropathy. 2022 Sep 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.

Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116:4754–61.CrossRefPubMed

Hoffmann JJ, Urrechaga E & Aguirre U. 2015 Discriminant indices for distinguishing thalassemia and iron deficiency in patients with microcytic anemia: a meta-analysis. Clin. Chem. Lab.Med53:1883–1894.

Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1(1):S9–18. https://doi.org/10.2215/CJN.01390406.CrossRefPubMed

Ooi CL, Lepage N, Nieuwenhuys E, Sharma AP, Filler G. Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. World J Pediatr. 2009;5:122–6.CrossRefPubMed

Core AB, Canali S, Babitt JL. Hemojuvelin and bone morphogenetic protein (BMP) signaling inironhomeostasis. FrontiersinPharmacology. 2014;5:104. https://doi.org/10.3389/fphar.2014.00104.PMC4026703.PMID24860505.CrossRef

Koury MJ. "Erythroferrone: A Missing Link in Iron Regulation". The Hematologist. American Society of Hematology. Archived from the original on 28 January 2019. Retrieved 26 August 2015. Hepcidin - Wikipedia. https://en.wikipedia.org/wiki/Hepcidin.

10.

Atkinson MA, Kim JY, Roy CN, Warady BA, White CT, Furth SL. Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort. Pediatr Nephrol. 2015;30(4):635–43. https://doi.org/10.1007/s00467-014-2991-4.

11.

Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet. 2014;46:678–84. https://doi.org/10.1038/ng.2996.CrossRefPubMedPubMedCentral

12.

Yalcin MM, Altinova AE, Akturk M, Gulbahar O, Arslan E, Ors Sendogan D, et al. GDF-15 and Hepcidin levels in nonanemic patients with impaired glucose tolerance. J Diabetes Res. 2016. https://doi.org/10.1155/2016/1240843.CrossRefPubMedPubMedCentral

13.

Mehmet MY, Alev EA, Akturk M, et al. GDF-15 and Hepcidin levels in nonanemic patients with impaired glucose tolerance. J Diabetes Res. 2016;2016:1–5.

14.

Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend AR, Robbins PA, et al. Regulation of growth differentiation factor 15 expression by intracellular iron. Blood. 2009;113(7):1555–63.CrossRefPubMed

15.

Abaza HM, Habashy DM, El-Nashar RE. Growth differentiation factor 15 expression in anemia of chronic disease and iron deficiency anemia. Egyptian J Haematology. 2013;38(1):23.CrossRef

16.

Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, et al. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study. Nephrol Dial Transplant. 2012;27(3):1076–83.CrossRefPubMed

17.

Peters HP, Laarakkers CM, Swinkels DW, Wetzels JF. Serum hepcidin-25 levels in patients with chronic kidney disease are independent of glomerular filtration rate. Nephrology Dialysis Transpl. 2010;25(3):848–53.CrossRef

18.

Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, et al. Hepcidin a potential novel biomarker for Iron status in chronic kidney disease. Clin J Am Soc Nephrology. 2009;4(6):1051–6.CrossRef

19.

Van der PK, Jie KE, van den BD, Kraaijenhagen RJ, Laarakkers C, Swinkels DW, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12(9):943–50.

20.

Tomosugi N, Kawabata H, Wakatabe R, Higuchi M, Yamaya H, Umehara H, Ishikawa I. Detection of serum hepcidin in renal failure and inflammation by using Protein Chip System. Blood. 2006;108(4):1381–7. https://doi.org/10.1182/blood-2005-10-4043.CrossRefPubMed

21.

Hayes W. Measurement of iron status in chronic kidney disease. Pediatr Nephrol. 2018;34(4):605–13.CrossRefPubMedPubMedCentral

22.

Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M. Immunoassay for human serum hepcidin. Blood. 2008;112(10):4292–7.CrossRefPubMed

23.

Yilmaz H, Cakmak M, Darcin T, Inan O, Bilgic MA, Bavbek N, et al. Can serum Gdf15 be associated with functional iron deficiency in hemodialysis patients? Indian J Hematol Blood Transfus. 2016;32(2):221–7.CrossRefPubMed

24.

Nalado AM, Olorunfemi G, Dix-Peek T, Dickens C, Khambule L, Snyman T, et al. Hepcidin and GDF-15 are potential biomarkers of Iron deficiency anaemia in chronic kidney disease patients in South Africa. BMC Nephrol. 2020;21:415.CrossRefPubMedPubMedCentral

25.

Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation. 2012;126(13):1596–604.CrossRefPubMed

26.

Li XY, Ying J, Li JH, Zhu SL, Li J, Pai P. Growth differentiation factor GDF-15 does not influence iron metabolism in stable chronic haemodialysis patients. Ann Clin Biochem. 2015;52(3):399–403.CrossRefPubMed

27.

Bargenda A, Musiał K, Zwolińska D. Epidermal growth factor, growth differentiation factor-15, and survivin as novel biocompatibility markers in children on chronic dialysis. Biomarkers. 2016;21(8):752–6.CrossRefPubMed

28.

Thorsteinsdottir H, Salvador CL, Mjøen G, Lie A, Sugulle M, Tøndel C, et al. Growth differentiation factor 15 in children with chronic kidney disease and after renal transplantation. Dis Markers. 2020;2020:6162892. https://doi.org/10.1155/2020/6162892, https://pubmed.ncbi.nlm.nih.gov/32089755/.

29.

Theurl I, Finkenstedt A, Schroll A, Nairz M, Sonnweber T, Bellmann-Weiler R, et al. Growth differentiation factor 15 in anaemia of chronic disease, iron deficiency anaemia and mixed type anaemia. Br J Haematol. 2010;148(3):449–55. https://doi.org/10.1111/j.1365-2141.2009.07961.x.CrossRefPubMed

30.

Mei SWH, Fu R, et al. Hepcidin and GDF15 in anemia of multiple myeloma. Int J Hematol. 2014;100:266–73.CrossRefPubMed

31.

De Haan JJ, Haitjema S, den Ruijter HM, Pasterkamp G, de Borst GJ, Teraa M, et al. Growth differentiation factor 15 is associated with major amputation and mortality in patients with peripheral artery disease. J Am Heart Assoc. 2017;6:9.

32.

Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion. 2010;50(7):1532–5.CrossRefPubMedPubMedCentral

33.

Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, et al. Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion. 2008;48(10):2197–204.CrossRefPubMed

34.

Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis Pediatr. Nephrol. 2014;29:2021–8.

Title: GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease
Authors: Naglaa Makram Farag
Mahmoud Mousa
Eman Elsayed
Ahlam Ismeil
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Chronic Kidney Disease
Anemia
Published in: Italian Journal of Pediatrics / Issue 1/2023
Electronic ISSN: 1824-7288
DOI: https://doi.org/10.1186/s13052-023-01505-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

GDF-15 and hepcidin as a therapeutic target for anemia in chronic kidney disease

Abstract

Background

Method

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

Tolosa-Hunt syndrome and recurrent painful ophthalmoplegic neuropathy, case reports: what to do and when?

Infant and Young Child Feeding practices up to 23 months in Namuno District, Cabo Delgado, Mozambique

Preschool-located influenza vaccination and influenza-like illness surveillance: an Italian pilot experience

Role of abnormal glycosylated IgA1 and interstitial transformation of glomerular endothelial cells in the development and progression of IgA nephropathy

Invasive Group A streptococcal infections: are we facing a new outbreak? A case series with the experience of a single tertiary center

Early acute cerebellar ataxia after meningococcal B vaccine: a case report of a 7-month-old infant and a review of the literature